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Abstract
Background: A hypertrophic scar is a unique fibrotic disease that only exists in humans. Despite advances in burn
care and rehabilitation, as well as progress in the management during these decades, the hypertrophic scar remains
hard to cure following surgical methods and drugs for treatment. In this study, we are looking forward to finding
the multitude of possible traumatic mechanisms and the underlying molecular signal ways in the formation of the
hypertrophic scar.
Methods: We used isobaric tags for relative and absolute quantitation (iTRAQ) labeling technology, followed by
high-throughput 2D LC-MS/MS, to determine relative quantitative differential proteins between the hypertrophic
scar and normal skin tissue.
Results: A total of 3166 proteins were identified with a high confidence (≥95 % confidence). And, a total of 89
proteins were identified as the differential proteins between the hypertrophic scar and normal skin, among which
41 proteins were up-regulated and 48 proteins were down-regulated in the hypertrophic scar. GO-Analysis
indicated the up-regulated proteins were involved in extracellular matrix, whereas the down-regulated proteins
were involved in dynamic junction and structural molecule activity.
Conclusions: In our study, we demonstrate 89 proteins present differently in the hypertrophic scar compared to
normal skin by iTRAQ technology, which might indicate the pathologic process of hypertrophic scar formation and
guide us to propose new strategies against the hypertrophic scar.
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Background
A hypertrophic scar, a unique fibrotic disease in humans
as no animals are known to form these lesions, presents
as erythematous, firm, elevated plaques that remain con-
fined to the area damaged by the initial injury [1]. Al-
though it does not pose a health risk, some scars may be
associated with pruritus, pain, disfigurement, disfunc-
tion, and psychological distress [2, 3]. Despite advances
in burn care and rehabilitation, as well as progress in the
management during these decades, the pathologic scar
remains hard to cure following surgical methods and
drugs for treatment [4, 5]. On this background, we are
looking forward to finding the multitude of possible
traumatic mechanisms and the underlying molecular sig-
nal ways in the formation of the hypertrophic scar.
In our previous studies, we have compared the global
gene profiling from the normal skin and hypertrophic
scar samples via cDNA microarray analysis [6]. The al-
tered genes were related to proto-oncogenes, apoptosis,
immune regulatory genes, cytoskeletal element, meta-
bolism, and so forth. Besides the genomic approach, we
further compared the protein profiles with a proteomic
approach in this study. The isobaric tags for relative and
absolute quantitation (iTRAQ) is a shotgun-based tech-
nique which allows the concurrent identification and
relative quantification of hundreds of proteins in up to
different biological samples in a single experiment [7].
With the iTRAQ approach, a large-scale evaluation of
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differential protein expression in the formation of the
hypertrophic scar may be valuable for finding scar-
related proteins or the potential target to control the
hypertrophic scar.
In this article, we revealed the differential proteomics
between the hypertrophic scar and normal skin tissues.
From three patients, 3166 proteins were screened by
iTRAQ. Forty-one up-regulated proteins were related to
extracellular matrix, and 48 down-regulated proteins
were involved in dynamic junction and structural mol-
ecule activity.
Methods
Tissue procurement and patient characteristics
The patient informed consent forms along with tissue
procurement procedures were approved by the Ethic
Committee of Southwest Hospital, Chongqing, China.
All the hypertrophic scar patients were selected accor-
ding to the Vancouver Scar Scale (VSS) ranging from a
score of 10 to 13. The hypertrophic scar tissues and the
normal skin tissues were obtained from the same pa-
tients who underwent orthopedic surgery at the Institute
of Burn Research of Southwest Hospital. The tissues
were frozen in liquid nitrogen immediately after surgical
removal and stored at −80 °C till sample preparation.
Reagents and chemicals
The chemical reagents acetonitrile, ethanol, methanol,
acetone, ammonium formate (high-performance liquid
chromatography (HPLC) grade), and trifluoroacetic acid
(TFA) were obtained from Sigma Corporation (Sigma,
USA) and Fisher Science Corporation (Thermo, USA).
The ultrapure-grade water, utilized for the HPLC and sub-
sequent tandem mass spectrometry (MS/MS) analysis
procedures, was generated from the MilliQ (Millipore,
USA)-type water. All iTRAQ reagents and buffers were
Table 1 A list of up-regulated proteins (n = 20) and
down-regulated proteins (n = 27) identified by iTRAQ
labeling combined with 2D LC-MS/MS
Accession Name Average fold
change




ENSP00000359153 Collagen, type XII, alpha 1 3.201809
ENSP00000362122 Tenomodulin 3.182895
ENSP00000300026 Peptidylprolyl isomerase B
(cyclophilin B)
3.071857
ENSP00000360882 Collagen, type V, alpha 1 2.865116
ENSP00000260356 Thrombospondin 1 2.668636
ENSP00000215909 Lectin, galactoside-binding, soluble, 1 2.555282
ENSP00000216336 Cathepsin G 2.541028
ENSP00000350894 Serpin peptidase inhibitor, clade H
(heat shock protein 47), member 1
2.502299
ENSP00000346839 Fibronectin 1 2.156667
ENSP00000265131 Tenascin C 2.12325
ENSP00000225964 Collagen, type I, alpha 1 1.998597
ENSP00000296511 Annexin A5 1.912369
ENSP00000254722 Serpin peptidase inhibitor, clade F,
member 1
1.89519
ENSP00000297268 Collagen, type I, alpha 2 1.88893
ENSP00000304408 Collagen, type III, alpha 1 1.855389
ENSP00000364711 Osteoglycin 1.713209
ENSP00000407788 Inner membrane protein,
mitochondrial (mitofilin)
0.69212




ENSP00000334983 Pyruvate kinase, muscle 2 0.626574
ENSP00000348965 Dynein, cytoplasmic 1, heavy chain 1 0.617843
ENSP00000200181 Integrin, beta 4 0.616907
ENSP00000417773 Transketolase 0.615061
ENSP00000344504 H1 histone family, member 0 0.587647
ENSP00000347190 Catenin (cadherin-associated protein),
alpha 1, 102 kDa
0.572509
ENSP00000343129 Tripartite motif-containing 29 0.571671
ENSP00000406273 Myosin, heavy chain 14, non-muscle 0.559878
ENSP00000375938 Tubulin, alpha 4a 0.54832
ENSP00000269576 Keratin 10 0.530142
ENSP00000331678 Plakophilin 3 0.521494
ENSP00000300036 Myosin, heavy chain 11,
smooth muscle
0.519123
ENSP00000377508 Junction plakoglobin 0.49407
ENSP00000353608 Desmocollin 3 0.490851
Table 1 A list of up-regulated proteins (n = 20) and
down-regulated proteins (n = 27) identified by iTRAQ
labeling combined with 2D LC-MS/MS (Continued)
ENSP00000301607 Envoplakin 0.487905
ENSP00000377550 Keratin 15 0.473652
ENSP00000420296 S100 calcium binding protein A14 0.418854
ENSP00000252242 Keratin 5 0.390976
ENSP00000295597 Plakophilin 1 (ectodermal dysplasia/
skin fragility syndrome)
0.35161
ENSP00000290158 Karyopherin (importin) beta 1 0.335195
ENSP00000363071 Desmin 0.330774
ENSP00000369129 Desmoplakin 0.326555
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obtained from Applied Biosystems (Applied Biosystems,
Foster City, CA, USA).
Protein extraction
The tissues were minced to pieces of approximately
2 mm in size. The pieces of tissues were grinded with a
mortar and pestle in liquid nitrogen. The soluble protein
was extracted according to the protocol in the Partial
Mammalian Proteome Extraction Kit (Calbiochem, USA).
A volume of 1 ml of extraction reagent 1, 5 μl of protease
inhibitor cocktail, and 500 μl glass beads were added im-
mediately into 250 mg of the tissue powder. The sample
was vortexed thoroughly for 1 min. After addition with a
volume of 4 μl of Benzonase® Nuclease (Novagen, USA),
the sample was incubated at 4 °C for 30 min at 500 rpm.
The solubilized sample was centrifuged at 15,000 rpm for
30 min at 4 °C after ultrasonication. Then the precipitate
was disintegrated with 1 ml detergent containing 500 μl
1 % (w/v) sodium dodecyl sulfate (SDS), 100 μl 1 % (v/v)
NP-40, and 400 μl 10 M urea. Subsequently, the sample
was incubated at 4 °C for 30 min at 500 rpm. And, the
protein of low solubility was extracted after the ultrasoni-
cation. The sample was centrifuged at 15,000 rpm for
30 min at 4 °C, and the protein in the supernatant mater-
ial was subjected to eight times the volume of ice-cold
acetone precipitation overnight before re-suspending into
0.1 % (w/v) SDS, 0.1 % (v/v) NP-40, and 1 M urea. The
soluble protein and the low soluble protein were quanti-
fied by the BCA protein assay kit (Pierce, USA) and stored
in aliquots at −80 °C until use.
In-solution digestion
The low soluble protein aliquot containing 250 μg of
total protein in 250 μl was reduced by the addition of
25 μl of 100 mM dithiothreitol (DTT; final concentra-
tion is 10 mM) followed by incubation at 56 °C for 1 h.
The reduced cysteine was alkylated by the addition of
25 μl of 550 mM IAA (final concentration is 55 mM)
(Fisher Science, USA) for 1 h at room temperature in a
dark condition. Then the unreacted IAA residues were
neutralized by the addition of 42.5 μl of 100 mM DTT
(final concentration is 17 mM). The protein was then
digested in a 1:50 trypsin/protein ratio at 37.5 °C
overnight. The digesting reaction was stopped by adding
367.5 μl of 0.1 % (v/v) TFA. The peptide samples were
then dried in a vacuum concentrator and re-suspended
by the addition of 250 μl of 0.1 % (v/v) TFA.
iTRAQ reagent label
Dried tryptic digests were desalted using a reverse-phase
system. The peptide samples were delivered to a Luna
C-18 column (1 × 100 mm, 5 μm, 100 Å; Waters
Corporation, Milford, MA, USA) and eluted by 80 %
acetonitrile. Subsequently, the samples were dried again
in the vacuum concentrator and re-suspended by the
iTRAQ Dissolution Buffer with vortex mixing for 1 h.
One unit of each iTRAQ reagent label (defined as the
amount needed to label 100 μg of protein) was thawed
and reconstituted in 70 μl of ethanol, with vortex mixing
for 1 min according to the manufacturer’s protocol. The
samples were mixed with the iTRAQ reagent for 1 h in
Fig. 1 Establishment of protein-protein interaction networks for scar/skin tissue differential proteins. The protein-protein interaction networks were
constructed by cytoscape software according the HPRD. Proteins are represented with grey nodes, and interactions are represented with edges.
a Scar significantly up-regulated PPI network was constructed, 20 of 41 scar-up-regulated proteins were included in the network. b Scar significantly
down-regulated PPI network was constructed, 27 of 48 scar-up-regulated proteins were included in the network
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a dark condition. A volume of 0.1 % TFA nine times the
sample volume was added into the samples. The result-
ing labeled peptide samples were then pooled and dried
in a vacuum concentrator before chromatographic frac-
tionation. The samples were iTRAQ labeled in duplicate.
First-dimensional HPLC analyses
The peptides were separated using a recently developed
two-dimensional liquid chromatographic method which
employs high pH reversed-phase separation in the first
dimension. The labeled mixed peptide samples derived
from approximately 200 μg of total protein were re-
suspended in 200 μl of HPLC buffer A and gradient frac-
tionated on a X-Terra C-18 column (1 × 100 mm, 5 μm,
100 Å; Waters Corporation, Milford, MA, USA) with a
constant flow rate of 150 μl/min. The buffer A consisted
of 20 mM ammonium formate (pH 10), and buffer B
(pH 10) consisted of 10 % of 20 mM ammonium for-
mate and 90 % of acetonitrile. The 65-min gradient
started with 1 % buffer B and 99 % buffer A, followed by
1 to 40 % buffer B2 for 60 min, then 90 % buffer B2 for
5 min. The chromatogram was monitored through a UV
detector. The UV wavelengths were set at 214 nm. Frac-
tions were collected every minute and later were pooled
together according to the variations in peak intensity.
Pooled fractions were dried in a vacuum concentrator
and stored at −80 °C until MS/MS analysis.
Second-dimensional liquid chromatography-electrospray
ionization-tandem mass spectrometry analysis
As described previously by Dwivedi et al. [8], a splitless
nano-flow Tempo LC system (Eksigent, Dublin, CA,
USA) with 20 μl sample (each dried labeled peptide
fraction was re-dissolved in 25 μl of eluent A containing
0.1 % formic acid in 2 % acetonitrile) injection via a
PepMap100 trap column (0.3× 5 mm, 5 μm, 100 Å;
Dionex Corporation, Sunnyvale, CA, USA) and a
100 μm× 150 mm analytical column packed with 5-μm
Luna C18(2) (Phenomenex, Torrance, CA, USA) was
used in the second-dimension separation prior to tan-
dem MS (MS/MS) analysis. Both eluents A (2 % aceto-
nitrile in water) and B (98 % acetonitrile) contained
0.1 % formic acid as an ion-pairing modifier. A 0.44 %
acetonitrile per minute linear gradient (0 to 35 % B in
Fig. 2 Scar-up-regulated PPI network was analyzed by BinGO plugin
in cytoscape software. a Biological process categories map. Map of
biological process categories associated with the scar-up-regulated PPI
network. b Cellular component map. Map of the cellular component
associated with the scar-up-regulated PPI network. c. Molecular
function map. Map of molecular function associated with scar-up-
regulated PPI network. Darker nodes refer to the significant ontologies
of the dataset. The size is proportional to the number of genes that
participate in that molecular function
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80 min, 500 nl/min) was used for peptide elution,
followed by a 5-min wash with 80 % B.
A QStar Elite QqTOF mass spectrometer (Applied
Biosystems) was used in standard MS/MS data-dependent
acquisition mode with a nano-electrospray ionization
source. Survey MS spectra were collected (m/z 400 to
1500) for 1 s followed by three MS/MS measurements on
the most intense parent ions (80 counts/s threshold, +2
to +4 charge state, and m/z 100 to 1500 mass range for
MS/MS), using the manufacturer’s “smart exit” and
“iTRAQ” settings. The “smart exit” option is a standard
feature of the QStar Elite instrument, which runs under
control of Analyst QS 2.0 software. It allows termination
of MS/MS spectrum collection when preset values of peak
intensity (quality of the spectra) are reached. In this way,
the instrument spends less time for MS/MS acquisition of
abundant species and improves chances for detection of
low-abundant ones. Spectral quality setting 5 (whole scale
1–20) was used throughout the experiments. Predefined
“iTRAQ” settings adjust (increase) collisional energy to
maximize the intensity of reporter ions (114, 115, 116,
117 Da) in MS/MS spectra. Individual Wiff files generated
after QStar Elite analysis were converted to mascot
generic file (MGF) format using Mascot.dll script in
Analyst QS 2.0. Following this conversion, MGF files of
individual fractions were combined into one using a mer-
ging script [9].
Database search and protein identification
The MS/MS data were analyzed using ProteinPilot
software version 2.0.1 (Applied Biosystems/MDS Sciex,
Concord, ON, Canada). The search parameters were
complete modifications of Cys alkylation with IAA, and
inbuilt iTRAQ analysis residue modifications settings were
on. Those protein candidates with greater than or equal to
95 % identification confidence were used for further ana-
lysis [8]. The annotation of protein cellular localization
and biological function was performed using PPI network
(Ingenuity Systems, Inc., Redwood City, CA, USA).
Results
Overview of proteomic changes in the hypertrophic scar
comparing normal skin
A detailed analysis of the proteomic changes was per-
formed using iTRAQ labeling. Reporters with masses of
114 and 115 were used to separately label biological repli-
cates of normal skin, and reporters with masses of 116 and
117 were used for replicates of the hypertrophic scar. The
four isobaric tag samples were mixed and analyzed by
2D-MS/MS. Relative protein levels were determined by
Fig. 3 Cluster analysis of the scar-up-regulated PPI network by MCODE plugin in cytoscape software. We identified eight genes belonging to the
highest cluster, i.e., the leader genes: COL1A1, COL1A2, COL3A1, COL5A1, COMP, FN1, THBS1, and TNC
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Fig. 5 Cluster analysis of the scar-down-regulated PPI network by MCODE plugin in cytoscape software. We identified five genes belonging to
the highest cluster, i.e., the leader genes: DSC3, DSP, EVPL, JUP, and PPL
Fig. 4 The scar-down-regulated PPI network was analyzed by BinGO plugin in cytoscape software. a Biological process categories map. Map of
biological process categories associated with the scar-down-regulated PPI network. b Cellular component map. Map of cellular component associated
with scar-down-regulated PPI network. c. Molecular function map. Map of molecular function associated with scar-down-regulated PPI network. Darker
nodes refer to the significant ontologies of the dataset. The size is proportional to the number of genes that participate in that molecular function
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comparing peak intensities of the four reporter ions re-
leased from each pool of purified, labeled peptides. We
identified 3166 distinct proteins. Eighty-nine proteins were
identified with a high confidence to up- or down-regulate
in the hypertrophic scar (Table 1).
Proteomic analysis of the differential up-regulated
expression proteins
Among these differential expressed proteins, 20 of 41 up-
regulated proteins (Fig. 1a) were analyzed by cytoscape
software to indicate a diversified functional network.
BinGO enrichment demonstrated that 20 up-regulated
protein categories were enriched in the biological process
(Fig. 2a), cellular component (Fig. 2b), and molecular func-
tion (Fig. 2c) categories. Among these proteins, extracellu-
lar matrices such as collagen, type I, alpha 1 (COL1A1);
collagen, type I, alpha 2 (COL1A2); collagen, type III, alpha
1 (COL3A1); collagen, type V, alpha 1 (COL5A1), cartilage
oligomeric matrix protein (COMP), fibronectin 1 (FN1),
thrombospondin 1 (THBS1), and tenascin C (TNC) were
identified to be the highest cluster (Fig. 3).
Proteomic analysis of the differential down-regulated
expression proteins
Twenty-seven of 48 down-regulated proteins were ana-
lyzed by cytoscape software to indicate a functional net-
work (Fig. 1b). A further 27 down-regulated proteins
were involved in the biological process (Fig. 4a), cellular
component (Fig. 4b), and molecular function (Fig. 4c)
categories. And five proteins including desmocollin 3
(DSC3), desmoplakin (DSP), envoplakin (EVPL), junc-
tion plakoglobin (JUP), and periplakin (PPL) were re-
lated to the highest cluster (Fig. 5).
Discussion
In this study, we use the iTRAQ method to screen the
differential proteins potentially involved in the hyper-
trophic scar compared to normal skin. Using 2D-MS/
MS followed by GO-Analysis, we demonstrate 89 pro-
teins with a high annotation confidence (≥95 %) present
differently in the hypertrophic scar. Among the differential
proteins, 41 proteins increased and 48 proteins decreased
in the hypertrophic scar. Consistent with previous studies,
the up-regulated proteins such as COL1A1, COL1A2,
COL3A1, COL5A1, COMP, FN1, THBS1, and TNC were
involved in extracellular matrix production, myofibroblast
contractility, and response to mechanical stress [10–13].
Interestingly, most of the down-regulated proteins, includ-
ing DSC3, DSP, EVPL, JUP, and PPL, were specific to the
epidermis and involved in the cell junction [14–18].
Some of the differentially expressed candidates identi-
fied by iTRAQ have previously been associated with
hypertrophic scar formation. Of the up-regulated pro-
teins, increased COL1A1, COL1A2, COL3A1, FN1, and
TNC expression have been reported in the hypertrophic
scar. COMP plays a role as a matrix deposition pro-
moter in the keloid (the special fibrotic skin disease)
[19]. It has been reported that THBS1 may modulate
keloid formation through up-regulation of the matrix
plasminogen/plasmin system [20]. However, no data re-
vealed the potential effects of COMP and THBS1 on the
hypertrophic scar formation. Our work for the first time
found COMP and THBS1 were up-regulated in the
hypertrophic scar, which might be attributed to a new
therapeutic target.
Conclusions
In summary, the iTRAQ analyses followed by the high-
throughput 2D LC-MS/MS in our study for the first time
screened protein expression of the hypertrophic scar and
normal skin tissue on a large scale from the same patients.
Some of the screened proteins in our study have been
reported in previous researches. However, some of the up-
regulated proteins such as COMP and THBS1 and the
down-regulated proteins could indicate that the patho-
logic process of hypertrophic scar formation which might
guide us to propose new strategies against the hyper-
trophic scar.
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